Cynata Therapeutics (ASX:CYP) Short-Term Capital Lease Obligation : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics Short-Term Capital Lease Obligation?

Cynata Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Cynata Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Cynata Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Short-Term Capital Lease Obligation Chart

Cynata Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

Cynata Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Cynata Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Cynata Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

51S:Germany

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines